{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:47:10Z","timestamp":1786981630285,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11102-023-01340-5","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:02:22Z","timestamp":1688961742000},"page":"474-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The treatment of aggressive prolactinomas with everolimus"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-261X","authenticated-orcid":false,"given":"Andrew L.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Page-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Magge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"2","key":"1340_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1340_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1340_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698. https:\/\/doi.org\/10.1210\/jc.2014-4350","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1340_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605. https:\/\/doi.org\/10.1530\/EJE-22-0440","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1340_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"issue":"6","key":"1340_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"4","key":"1340_CR7","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E et al (2014) The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 21(4):R331\u2013R344. https:\/\/doi.org\/10.1530\/ERC-14-0188","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1340_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D et al (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929\u20131936. https:\/\/doi.org\/10.1210\/jc.2018-02461","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1340_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"issue":"3","key":"1340_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228\u2013243. https:\/\/doi.org\/10.1007\/s12022-017-9498-z","journal-title":"Endocr Pathol"},{"issue":"1","key":"1340_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL et al (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33(1):6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"issue":"1","key":"1340_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol"},{"issue":"18","key":"1340_CR13","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma\u202f: final results and analysis of prognostic factors. Cancer 116(18):4256\u20134265. https:\/\/doi.org\/10.1002\/cncr.25219","journal-title":"Cancer"},{"issue":"3","key":"1340_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","volume":"182","author":"DA White","year":"2010","unstructured":"White DA et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182(3):396\u2013403. https:\/\/doi.org\/10.1164\/rccm.200911-1720OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1340_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS et al (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18(5):654\u2013662. https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"issue":"2","key":"1340_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","volume":"46","author":"O Cooper","year":"2014","unstructured":"Cooper O et al (2014) Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine 46(2):318\u2013327. https:\/\/doi.org\/10.1007\/s12020-013-0093-x","journal-title":"Endocrine"},{"issue":"2","key":"1340_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1210\/en.2008-0756","volume":"150","author":"N Ben-Jonathan","year":"2009","unstructured":"Ben-Jonathan N et al (2009) Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 150(2):795\u2013802. https:\/\/doi.org\/10.1210\/en.2008-0756","journal-title":"Endocrinology"},{"issue":"1","key":"1340_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1210\/me.2010-0353","volume":"25","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H et al (2011) HER2\/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol 25(1):92\u2013103. https:\/\/doi.org\/10.1210\/me.2010-0353","journal-title":"Mol Endocrinol"},{"issue":"2","key":"1340_CR19","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O et al (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925. https:\/\/doi.org\/10.1210\/clinem\/dgaa805","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1340_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00280-013-2297-4","volume":"72","author":"SM Gadgeel","year":"2013","unstructured":"Gadgeel SM et al (2013) Phase I study evaluating the combination of lapatinib (a Her2\/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 72(5):1089\u20131096. https:\/\/doi.org\/10.1007\/s00280-013-2297-4","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01340-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:20:15Z","timestamp":1690946415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01340-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01340-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"3 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew L. Lin reports that he has received funding from Bristol-Myers Squibb. Robert J. Young reports that he has consulted for Olea Sphere and ICON plc, unrelated to this work. The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted using a waiver of informed consent that was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}